A healthcare startup called Invenio Imaging is developing technology that enables surgeons to evaluate tissue biopsies in the operating room, immediately after samples are collected. This technology uses artificial intelligence (AI) to provide surgeons with insights that would otherwise take weeks to obtain from a pathology lab.
Invenio’s NIO Laser Imaging System is a digital pathology tool that accelerates the imaging of fresh tissue biopsies. It’s been used in thousands of procedures in the U.S. and Europe, and it received the CE Mark of regulatory approval in Europe in 2021. The company plans to adopt the NVIDIA Jetson Orin series of edge AI modules for its next-generation imaging system, which will feature near real-time AI inference accelerated by the NVIDIA TensorRT SDK.
The NIO Laser Imaging System works by scanning tissue samples with a laser and capturing images of the cells. The AI software then analyzes the images and provides surgeons with information about the type and grade of cancer, as well as the presence of any other abnormalities. This information can help surgeons to make more informed decisions about the course of surgery and the patient’s treatment plan.
The NIO Laser Imaging System has a number of potential benefits for patients and surgeons. For patients, it can reduce the time they have to wait for a definitive diagnosis and treatment plan. For surgeons, it can help them to make more accurate and timely decisions during surgery. This can lead to better outcomes for patients and a reduction in the risk of complications.
In addition to its use in cancer surgery, the NIO Laser Imaging System could also be used to diagnose other diseases, such as heart disease and neurological disorders. Invenio Imaging is currently conducting clinical trials to evaluate the use of the system for these applications.
Invenio Imaging’s technology has the potential to revolutionize the way that cancer is diagnosed and treated. By using AI to analyze cancer cells in the operating room, surgeons can make more informed decisions about the course of surgery and the patient’s treatment plan. This can lead to better outcomes for patients and a reduction in the risk of complications.